JSH-23: Selective NF-κB Inhibitor for Inflammation Research

Executive Summary: JSH-23 (CAS 749886-87-1) is a small-molecule inhibitor that blocks NF-κB p65 nuclear translocation and DNA binding, with an IC₅₀ of approximately 7.1 μM in cell-based assays (APExBIO). The compound does not interfere with IκB degradation, making it a precise tool for dissecting NF-κB-mediated transcriptional responses (Zhou et al., 2023). In LPS-stimulated macrophages, JSH-23 suppresses key pro-inflammatory mediators, including IL-6 and TNF-α, confirming target engagement. In vivo, JSH-23 reduces biomarkers and tissue injury in cisplatin-induced acute kidney injury models. Its solubility profile and stability parameters facilitate integration into standard molecular biology workflows.

Biological Rationale

The NF-κB pathway is a central mediator of inflammatory and immune responses. Upon activation by stimuli such as LPS or viral infection, NF-κB translocates to the nucleus and promotes transcription of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α (Zhou et al., 2023). These cytokines are essential in acute and chronic inflammation, as well as host defense and disease pathogenesis. Dysregulation of NF-κB activity is implicated in autoimmune, infectious, and oncological diseases. Small-molecule inhibitors targeting specific steps of the NF-κB cascade are valuable for mechanistic dissection and therapeutic development. JSH-23, offered by APExBIO, is designed to selectively inhibit nuclear translocation and transcriptional activity of the p65 subunit, leaving upstream cytoplasmic signaling intact (APExBIO). This specificity aids in distinguishing nuclear signaling events from cytoplasmic regulatory controls.

Mechanism of Action of JSH-23

JSH-23 (4-methyl-1-N-(3-phenylpropyl)benzene-1,2-diamine) acts as a selective inhibitor of NF-κB-driven gene transcription. It achieves this by reducing nuclear localization and subsequent DNA binding of the NF-κB p65 subunit (Zhou et al., 2023). Importantly, JSH-23 does not interfere with the degradation of IκB, the upstream cytoplasmic inhibitor of NF-κB. This was demonstrated in multiple cell-based models, including LPS-stimulated RAW 264.7 macrophages, where JSH-23 maintained IκB degradation dynamics while reducing nuclear p65 levels and downstream cytokine output. The compound's action is thus localized to the nuclear phase of NF-κB signaling, making it particularly suitable for studies focusing on transcriptional regulation and chromatin-level mechanisms. JSH-23's molecular weight is 240.34 Da, and its chemical formula is C₁₆H₂₀N₂. It is insoluble in water but dissolves in DMSO (≥24 mg/mL) and ethanol (≥17.1 mg/mL with sonication).

Evidence & Benchmarks

• JSH-23 inhibits NF-κB-driven transcription with an IC₅₀ of ~7.1 μM in cell-based reporter assays (APExBIO).
• In LPS-stimulated RAW 264.7 macrophages, JSH-23 reduces expression of IL-6, IL-1β, COX-2, and TNF-α (see Figure 2, Zhou et al., 2023).
• JSH-23 does not affect the kinetics or extent of IκB degradation, as shown by Western blot (see Figure 3, Zhou et al., 2023).
• In cisplatin-induced acute kidney injury in C57BL/6 mice, JSH-23 administration (intraperitoneal) decreased BUN, serum creatinine, NGAL, IL-1, IL-6, CXCL1, and TNF-α, and lowered tubular necrosis scores (see Table 1, APExBIO).
• JSH-23 inhibits apoptotic chromatin condensation in inflammation models (JSH-23: A Next-Gen NF-κB Inhibitor).

This article extends the mechanistic analysis found in "JSH-23: A Next-Generation Tool for NF-κB Pathway Dissection" by providing updated in vivo benchmarks and storage guidelines. For advanced troubleshooting and protocols, see "JSH-23: Optimizing NF-κB Inhibition for Inflammation Research". Our focus here is on specificity and translational applicability.

Applications, Limits & Misconceptions

JSH-23 is widely used in:

• Cellular studies dissecting nuclear NF-κB transcriptional events.
• Profiling cytokine responses in immune cell lines and primary macrophages.
• In vivo models, such as cisplatin-induced acute kidney injury, to probe the role of NF-κB in tissue inflammation and damage.
• Validation of NF-κB-dependent gene regulation without perturbing cytoplasmic signaling.

For a transformative view on its utility in emerging in vivo models, see "JSH-23: A Transformative Tool for Dissecting NF-κB-Driven Inflammation", which this article updates with new animal model data and refined solubility handling.

Common Pitfalls or Misconceptions

• JSH-23 is not suitable for studies requiring inhibition of upstream NF-κB activation (e.g., IκB kinase or IκB degradation).
• The compound is insoluble in aqueous buffers and must be prepared in DMSO or ethanol; improper solvent selection leads to precipitation and assay artifacts.
• Solutions of JSH-23 should not be stored long-term; fresh preparation is recommended for each experiment to ensure potency (APExBIO).
• JSH-23 does not block inflammasome or TLR signaling directly; effects are limited to nuclear NF-κB events (Zhou et al., 2023).
• Off-target effects have not been extensively profiled in non-mammalian systems, so cross-species extrapolation requires caution.

Workflow Integration & Parameters

Solubility & Preparation: JSH-23 is supplied as a solid. Dissolve at ≥24 mg/mL in DMSO or ≥17.1 mg/mL in ethanol with ultrasonic assistance. Solutions are stable for short-term use; avoid long-term storage by preparing fresh aliquots (APExBIO).

Experimental Conditions: In vitro, use at 1–20 μM depending on cell type and endpoint. In vivo, intraperitoneal dosing in mice has shown efficacy at 10–30 mg/kg in acute inflammation models.

Storage: Store solid at -20°C, protected from light and moisture.

For advanced troubleshooting, protocol optimization, and comparison with other NF-κB inhibitors, see "JSH-23: Precision NF-κB Inhibitor for Advanced Inflammation Models". This complements the present article by focusing on assay design and parameterization.

Conclusion & Outlook

JSH-23 is a selective tool compound enabling precise inhibition of NF-κB p65 nuclear translocation and downstream gene transcription. Its lack of effect on upstream cytoplasmic events, combined with robust in vitro and in vivo efficacy, underpins its value for mechanistic and translational inflammation research. Careful attention to solubility, storage, and context of use maximizes reproducibility. As new models of inflammatory disease emerge, JSH-23's specificity positions it as a critical standard for dissecting nuclear aspects of NF-κB signaling. For detailed product information, refer to the APExBIO JSH-23 product page.